Biotest AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIESF research report →
Price Chart
About the company
Biotest Aktiengesellschaft is a global developer, manufacturer, and supplier of biological medicines. Operating through its Therapy, Plasma & Services, and Other segments, the company focuses on therapeutic areas including hematology, clinical immunology, and intensive care medicine. Its product offerings encompass treatments for hemophilia, such as Haemoctin and Vihuma for acute therapy and prophylaxis of hemophilia A, and Haemonine for hemophilia B.
- CEO
- Jorg Schuttrumpf
- IPO
- 2014
- Employees
- 2,495
- HQ
- Dreieich, DE
Get TickerSpark's AI analysis on BIESF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.60B
- P/E
- 48.06
- PEG
- -0.42
- P/S
- 2.18
- P/B
- 2.40
- EV/EBITDA
- 17.22
- Div Yield
- 0.25%
- Gross Margin
- 30.82%
- Op Margin
- 13.01%
- Net Margin
- 3.64%
- ROE
- 5.13%
- ROIC
- 4.18%
Latest fiscal year · YoY change
- Revenue
- $648.66M-10.7%
- Gross Profit
- $61.88M-72.4%
- Op Income
- $-48,581,797
- Net Income
- $-70,673,520-367.7%
- EPS
- $-1.79-352.1%
- OCF Growth
- -335.9%
- FCF Growth
- -580.9%
- 52W High
- $32.00
- 52W Low
- $30.48
- 50D MA
- $32.00
- 200D MA
- $30.98
- Beta
- 0.17
- RSI (14)
- 100
- Avg Volume
- 75
No earnings-call transcripts are available for BIESF yet.
- Free Float
- 40.0%
- Shares Outstanding
- 49.99M
- Float Shares
- 20.01M
Our BIESF coverage
Recent articles, reports, and earnings notes.
No research on BIESF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIESF report →